Tildrakizumab (Ilumetri)

Indications

Treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy

Sizes Available

A subcutaneous injection for plaque psoriasis containing the active ingredient tildrakizumab, which acts on cytokine IL-23.

More on: Systemic psoriasis treatments